Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

N Engl J Med. 2024 May 2;390(17):1633-1634. doi: 10.1056/NEJMc2402472.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adenine / analogs & derivatives
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers / analysis
  • Biomarkers / blood
  • Bone Marrow / pathology
  • Bridged Bicyclo Compounds, Heterocyclic
  • Cyclophosphamide / administration & dosage
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / blood
  • Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Neoplasm, Residual* / blood
  • Neoplasm, Residual* / diagnosis
  • Neoplasm, Residual* / drug therapy
  • Piperidines
  • Randomized Controlled Trials as Topic
  • Rituximab / administration & dosage
  • Sulfonamides
  • Survival Analysis
  • Vidarabine / analogs & derivatives

Substances

  • Rituximab
  • Cyclophosphamide
  • Biomarkers
  • ibrutinib
  • Adenine
  • Piperidines
  • fludarabine
  • Vidarabine
  • venetoclax
  • Sulfonamides
  • Bridged Bicyclo Compounds, Heterocyclic